NCT01730937

Clinical Trial Information

Trial Number: NCT01730937 (ClinicalTrials.gov)

Disease Type:

Gastrointestinal Neoplasm - Liver and Hepatobiliary Cancer

Trial Title:

"Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma"

Study ID:

RTOG-1112

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01730937-D5	This dataset, NCT01730937-D5, contains imputed data used to calculate the percent of patients with improvement in the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep)[version 4] total score from baseline to 6 months presented in the RTOG-1112 primary publication (PMID: 39699905). NCT01730937-D1 contains baseline, treatment, outcome, toxicity, and quality of life data. NCT01730937-D2 contains adverse event system organ class data regardless of relationship to treatment. NCT01730937-D3 contains specific adverse event term data regardless of relationship to treatment. NCT01730937-D4 contains specific treatment-related adverse event term data.
NCT01730937-D4	This dataset, NCT01730937-D4, contains specific treatment-related adverse event term data presented in the RTOG-1112 primary publication (PMID: 39699905). NCT01730937-D1 contains baseline, treatment, outcome, toxicity, and quality of life data. NCT01730937-D2 contains adverse event system organ class data regardless of relationship to treatment. NCT01730937-D3 contains specific adverse event term data regardless of relationship to treatment. NCT01730937-D5 contains imputed data used to calculate the percent of patients with improvement in the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep)[version 4] total score from baseline to 6 months.
NCT01730937-D3	This dataset, NCT01730937-D3, contains specific adverse event term data regardless of relationship to treatment presented in the RTOG-1112 primary publication (PMID: 39699905). NCT01730937-D1 contains baseline, treatment, outcome, toxicity, and quality of life data. NCT01730937-D2 contains adverse event system organ class data regardless of relationship to treatment. NCT01730937-D4 contains specific treatment-related adverse event term data. NCT01730937-D5 contains imputed data used to calculate the percent of patients with improvement in the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep)[version 4] total score from baseline to 6 months.
NCT01730937-D2	This dataset, NCT01730937-D2, contains adverse event system organ class data regardless of relationship to treatment presented in the RTOG-1112 primary publication (PMID: 39699905). NCT01730937-D1 contains baseline, treatment, outcome, toxicity, and quality of life data. NCT01730937-D3 contains specific adverse event term data regardless of relationship to treatment. NCT01730937-D4 contains specific treatment-related adverse event term data. NCT01730937-D5 contains imputed data used to calculate the percent of patients with improvement in the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep)[version 4] total score from baseline to 6 months.
NCT01730937-D1	This dataset, NCT01730937-D1, contains baseline, treatment, outcome, toxicity, and quality of life data presented in the RTOG-1112 primary publication (PMID: 39699905). NCT01730937-D2 contains adverse event system organ class data regardless of relationship to treatment. NCT01730937-D3 contains specific adverse event term data regardless of relationship to treatment. NCT01730937-D4 contains specific treatment-related adverse event term data. NCT01730937-D5 contains imputed data used to calculate the percent of patients with improvement in the Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep)[version 4] total score from baseline to 6 months.

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®